The 340B Drug Pricing Program is approaching a significant change. Beginning January 1, 2027, certain pharmaceutical manufacturers will be permitted to replace the traditional upfront 340B discount with a retrospective rebate model for designated drugs. For hospitals, federally qualified health centers (FQHCs), and other 340B covered entities, this change could create substantial financial and operational challenges, including increased upfront drug acquisition costs, additional administrative responsibilities, and potential delays in receiving 340B savings.
The Health Resources and Services Administration (HRSA) has approved rebate plans submitted by ten pharmaceutical manufacturers covering 21 drugs. Although the revised program includes safeguards intended to protect covered entities, significant questions remain concerning its implementation, financial consequences, and legality.
Covered entities should begin preparing now, while also monitoring ongoing litigation that could delay or prevent the program’s implementation.
How Will the 340B Rebate Model Pilot Program Work?
Historically, covered entities have purchased eligible outpatient drugs at or below the applicable 340B ceiling price, receiving the statutory discount at the time of purchase. Under the new 340B Rebate Model Pilot Program, covered entities will instead purchase designated drugs at wholesale acquisition cost (WAC), then submit claims-level data to obtain a rebate equal to the difference between WAC and the applicable 340B ceiling price.
For example, a covered entity that historically purchased a medication for $250 under the 340B program might instead pay $1,000 upfront and subsequently seek a $750 rebate. Although the ultimate acquisition cost should theoretically remain unchanged, the covered entity must initially finance the higher purchase price, submit the required data, and ensure the manufacturer processes and pays the rebate in a timely manner.
The pilot applies to specified drugs selected for Medicare drug price negotiations for 2026 and 2027. Importantly, the rebate requirements are not limited to Medicare claims. They may apply to eligible 340B transactions involving commercially insured, Medicaid, and uninsured patients, as well as physician-administered medications.
On October 1, 2026, HRSA announced the approval of plans submitted by AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, GSK, Merck, Pfizer, and Teva. Affected products include Eliquis, Jardiance, Farxiga, Januvia, Enbrel, Imbruvica, and Ibrance, among others. The approved plans will use the Beacon Rebate Model Platform to facilitate the submission and processing of rebate requests.
What Safeguards Has HRSA Implemented?
In response to criticisms of the original 340B rebate pilot, the revised program includes several protections intended to reduce the administrative and financial burdens associated with retrospective rebates.
Ten-Day Rebate Processing Requirement.
Manufacturers must pay or deny rebate requests within ten calendar days after receiving a complete submission. However, the payment clock may restart if a submission is deemed incomplete and must be resubmitted.
Standardized Claims-Level Data Requirements.
Manufacturers may request only HRSA-approved data fields. This is intended to reduce administrative complexity and prevent manufacturers from imposing additional reporting conditions beyond those authorized under the pilot.
Restrictions on Rebate Denials.
Manufacturers cannot deny rebate requests based on alleged diversion or Medicaid duplicate-discount violations. Those issues must be addressed through established 340B compliance mechanisms.
Unit-Level Rebates.
Covered entities may obtain rebates for individual eligible units without waiting to accumulate an entire package for replenishment.
Manufacturer Accountability.
Covered entities must have access to rebate status information and mechanisms for escalating disputes. HRSA may revoke a manufacturer’s authorization to participate in the pilot for systemic noncompliance.
Despite these safeguards, the most significant financial concerns remain unresolved. Under the rebate program, covered entities must finance the difference between WAC and the 340B ceiling price until rebates are received.
HRSA has suggested that the ten-day payment requirement should generally allow covered entities to receive rebates before their wholesaler invoices become due. However, this assumption may not hold true for entities purchasing inventory in advance, maintaining shorter wholesaler payment terms, or experiencing delays in dispensing or submitting claims. Even when manufacturers comply with the payment deadline, covered entities may experience substantial increases in working-capital requirements that could affect their ability to fund operations and patient services.
Could the Revised 340B Rebate Program Face Another Legal Challenge?
The revised pilot follows a successful legal challenge to HRSA’s original rebate program. In American Hospital Association v. Kennedy, hospital associations and individual hospitals challenged HRSA’s initial authorization of a rebate pilot scheduled to begin January 1, 2026.
On December 29, 2025, the U.S. District Court for the District of Maine issued a preliminary injunction preventing implementation. The court concluded that the plaintiffs were likely to succeed on their claims that HRSA acted arbitrarily and capriciously under the Administrative Procedure Act (APA). In particular, the court found that HRSA failed to adequately consider covered entities’ reliance on upfront 340B discounts and the financial and administrative burdens associated with transitioning to retrospective rebates.
Following the original injunction, HRSA undertook a revised administrative process, soliciting stakeholder comments and developing a more extensive record addressing financial burdens, reliance interests, and implementation concerns. The revised program therefore presents a different legal posture from its predecessor. Nevertheless, significant questions remain concerning whether HRSA has adequately evaluated the actual financial consequences of the rebate model.
For example, HRSA’s analysis may be challenged for relying on generalized assumptions concerning wholesaler payment terms, rebate processing times, and covered entities’ ability to absorb increased acquisition costs. Similarly, covered entities may argue that HRSA inadequately evaluated the impact on financially vulnerable hospitals and health centers, particularly those with limited operating reserves or substantial utilization of high-cost specialty medications.
On October 9, 2026, the American Hospital Association (AHA), the Maine Hospital Association and four safety-net hospitals filed a new lawsuit in the U.S. District Court for the District of Maine challenging this new rebate pilot, once again, seeking to halt the program’s implementation prior to January 1, 2027. The renewed challenge squarely focuses on whether HRSA’s revised analysis reasonably addresses these concerns, rather than merely acknowledging their existence. Importantly, AHA now argues that HRSA’s revised analysis is fundamentally defective, relies on unsupported assumptions, ignores specific categories of costs, and applies the wrong legal standard when determining whether a rebate mechanism is permissible. Covered entities should monitor the litigation closely while continuing to prepare for the January 1, 2027, implementation date unless the program is delayed or otherwise modified.
What Should Covered Entities Do Now?
With implementation approaching, covered entities should take several steps to protect their financial and operational interests.
1. Identify affected drugs and estimate financial exposure.
Covered entities should review their utilization of the drugs included in the approved rebate plans and calculate the difference between current 340B acquisition costs and anticipated WAC purchases. This analysis should account for inventory turnover, wholesaler payment terms, and potential delays in receiving rebates to assess cash-flow needs and working-capital exposure.
2. Review wholesaler and third-party administrator arrangements.
Covered entities should confirm how purchases will be processed through existing 340B wholesaler accounts and whether current replenishment, inventory, and claims-processing systems can accommodate retrospective rebates. They should also identify any necessary changes to vendor agreements, workflows, or technology systems before implementation.
3. Establish claims submission and reconciliation procedures.
The pilot generally requires rebate submissions within 45 calendar days of dispensing, subject to specified exceptions. Covered entities should implement procedures to ensure timely submissions, identify rejected rebate requests, track outstanding rebates, and reconcile payments against eligible transactions.
4. Evaluate data-sharing obligations.
Covered entities should review the approved manufacturer plans, reporting requirements, and technology-platform arrangements to understand what claims-level information must be disclosed, how it may be used, and what protections apply. They should also assess applicable privacy, confidentiality, and data-security considerations.
5. Develop procedures for challenging improper denials.
Covered entities should maintain documentation supporting rebate eligibility and establish processes for escalating delayed or denied payments to manufacturers and HRSA. These procedures should include tracking submission dates, manufacturer responses, and unresolved disputes.
How Frier Levitt Can Help
The 340B Rebate Model Pilot Program represents more than a change in how discounts are processed. It shifts significant financial and administrative responsibilities to covered entities while providing manufacturers with greater visibility into individual 340B transactions. Although HRSA has implemented safeguards intended to facilitate timely rebate payments, the transition may create substantial cash-flow pressures and operational challenges, particularly for covered entities that depend heavily on 340B savings to support patient services.
As covered entities prepare for the January 2027 implementation, Frier Levitt can help evaluate the financial, operational, and legal implications of the rebate model, review manufacturer requirements, and address compliance and reimbursement disputes. Our attorneys also advise covered entities on 340B contract pharmacy restrictions, claims-level and encounter-level data requirements, manufacturer audits, and other policies affecting 340B program participation. Contact Frier Levitt to discuss how these developments may affect your organization and the steps you can take to prepare.
